Established in 2022, Goway Medicine is dedicated to developing a high-dimensional biology and AI-driven drug design platform, aiming to offer innovative drug solutions for critical diseases. The company recently declared the successful closure of its Pre-A round financing, with total funds raised amounting to hundreds of millions of yuan this year. This funding round was co-led by Huatai GenScript Fund and Orient Gene, with contributions from various institutions and follow-on investments from current shareholders. Cipher Capital acted as the exclusive financial advisor. The proceeds will be allocated towards advancing the AI target discovery platform, conducting clinical trials for the core product GW-01, and undertaking preclinical research on new drug candidates. GW-01 represents Goway Medicine's pioneering small-molecule drug on a global scale to reach the clinical phase, backed by the National Science and Technology Major Project. Both Chinese and U.S. clinical applications have been granted expedited approval, and the Phase I clinical trial has begun patient recruitment. This drug has effectively tackled the longstanding hurdle of targeting the Notch pathway, progressing from target identification to clinical development in under three years, thereby affirming the platform's efficacy and the team's implementation prowess (adjusted from "execution capabilities" to better fit English expression habits, conveying the team's strong ability to put plans into action). Presently, the company is expediting the development of multiple distinct drug pipelines, with several preclinical projects anticipated to transition into clinical stages. Recently, the company unveiled the ACUMEN proximity-induced platform and the NEXUS universal neoantigen discovery platform, creating strategic synergy with the existing GROOVY platform. This integration has resulted in a comprehensive AI-driven target discovery system encompassing diverse drug modalities, positioning Goway Medicine as one of the select few AI-driven drug discovery platform companies in China capable of target discovery across all drug types. Concurrently, the company is constructing a global model for AI target discovery to boost the efficiency and success rate of developing First-in-Class drugs. The founder of the company, along with both new and existing shareholders from this funding round, have expressed their approval of the company's platform capabilities, pipeline advancements, and growth prospects. They will collaborate to facilitate the transformation of original innovations into clinical benefits, offering more groundbreaking treatment options to patients worldwide.